Italy's Angelini to Buy Catalyst Pharma for $4.1 Billion in US Market ...
The deal gives Angelini Pharma a rare-disease portfolio and U.S. commercial platform as it targets growth in North America, the companies said.
- On Thursday, May 7, 2026, Italian pharmaceutical company Angelini Pharma announced a definitive agreement to acquire Catalyst Pharmaceuticals for $4.1 billion in cash, marking the drugmaker's entry into the U.S. pharmaceutical market.
- This acquisition reinforces Angelini Pharma's long-term commitment to Brain Health and Rare Diseases, establishing the company as a global player with the scale and capabilities needed to expand into the United States.
- Angelini will pay $31.50 per share, a 28% premium, for Catalyst's portfolio including FDA-approved treatments FIRDAPSE, AGAMREE, and FYCOMPA, which Catalyst acquired from Eisai in 2023.
- Catalyst CEO Rich Daly called the acquisition a "pivotal and transformative moment," saying the combined platform will enhance patient support and accelerate innovation for stakeholders worldwide.
- Separately, Catalyst resolved patent litigation regarding a generic version of FIRDAPSE filed by Hetero USA, while the transaction remains subject to regulatory approval with closing expected in the third quarter of 2026.
10 Articles
10 Articles
The transaction marks the entry of Italian society into the US market and its strengthening in the area of the nervous system and rare diseases
Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
The Italian company Angelini Pharma said Thursday it would buy the rare-disease focused Catalyst Pharmaceuticals for roughly $4.1 billion in cash. The deal values Florida-based Catalyst at $31.50 a share, a 28% premium to the 30-day period before April 22, when it became publicly known that a deal was in the works. Buying Catalyst, which sells three approved medicines, will give Angelini a foothold in the U.S. market. It also builds on its wor…
Globe Newswire
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease
Angelini Pharma has entered into a definitive agreement to acquire Catalyst Pharmaceuticals....
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the
The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration of approximately 4.1 billion USD, representing a premium of 28% to the 30-day volume-weighted average trading price as of April 22, 2026 The transaction marks Angelini Pharma's entry into the U.S. market, reinforcing its long-term commitment to Brai…
Coverage Details
Bias Distribution
- 63% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
